156 related articles for article (PubMed ID: 16702183)
1. Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention.
Lokiec F
Ann Oncol; 2006 May; 17 Suppl 4():iv33-6. PubMed ID: 16702183
[TBL] [Abstract][Full Text] [Related]
2. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo.
Börner K; Kisro J; Brüggemann SK; Hagenah W; Peters SO; Wagner T
Drug Metab Dispos; 2000 May; 28(5):573-6. PubMed ID: 10772637
[TBL] [Abstract][Full Text] [Related]
4. Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignancies.
Kiewe P; Neumann M; Wagner T; Seyfert S; Albrecht H; Thiel E; Korfel A
Cancer Chemother Pharmacol; 2011 Jan; 67(1):27-33. PubMed ID: 20182727
[TBL] [Abstract][Full Text] [Related]
5. Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models.
Leclerc E; Hamon J; Bois FY
J Appl Toxicol; 2016 Feb; 36(2):330-9. PubMed ID: 26152902
[TBL] [Abstract][Full Text] [Related]
6. Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors.
Kiewe P; Thiel E; Reinwald M; Korfel A
J Neurooncol; 2011 Jul; 103(3):629-34. PubMed ID: 20941526
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma.
Jahnke K; Wagner T; Bechrakis NE; Willerding G; Coupland SE; Fischer L; Thiel E; Korfel A
Ann Oncol; 2005 Dec; 16(12):1974-8. PubMed ID: 16219622
[TBL] [Abstract][Full Text] [Related]
8. Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.
Calinski DM; Zhang H; Ludeman S; Dolan ME; Hollenberg PF
Drug Metab Dispos; 2015 Jul; 43(7):1084-90. PubMed ID: 25934575
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.
Boddy AV; English M; Pearson AD; Idle JR; Skinner R
Eur J Cancer; 1996 Jun; 32A(7):1179-84. PubMed ID: 8758250
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.
Willits I; Price L; Parry A; Tilby MJ; Ford D; Cholerton S; Pearson AD; Boddy AV
Br J Cancer; 2005 May; 92(9):1626-35. PubMed ID: 15827549
[TBL] [Abstract][Full Text] [Related]
11. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
Kansara R
Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
[TBL] [Abstract][Full Text] [Related]
12. Poly-isoprenylated ifosfamide analogs: Preactivated antitumor agents as free formulation or nanoassemblies.
Skarbek C; Delahousse J; Pioche-Durieu C; Baconnais S; Deroussent A; Renevret P; Rivard M; Desmaele D; Martens T; Le Cam E; Couvreur P; Paci A
Int J Pharm; 2017 Nov; 532(2):748-756. PubMed ID: 28546071
[TBL] [Abstract][Full Text] [Related]
13. Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans.
Lokiec F; Santoni J; Weill S; Tubiana-Hulin M
Anticancer Drugs; 1996 Nov; 7(8):893-6. PubMed ID: 8991196
[TBL] [Abstract][Full Text] [Related]
14. Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma.
Fischer L; Korfel A; Kiewe P; Neumann M; Jahnke K; Thiel E
Ann Hematol; 2009 Feb; 88(2):133-9. PubMed ID: 18679681
[TBL] [Abstract][Full Text] [Related]
15. Assessment of glucosylifosfamide mustard biodistribution in rats with prostate adenocarcinomas by means of in vivo 31P NMR and in vitro uptake experiments.
Haberkorn U; Krems B; Gerlach L; Bachert P; Morr I; Wiessler M; van Kaick G
Magn Reson Med; 1998 May; 39(5):754-61. PubMed ID: 9581607
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide-induced nephrotoxicity: mechanism and prevention.
Nissim I; Horyn O; Daikhin Y; Nissim I; Luhovyy B; Phillips PC; Yudkoff M
Cancer Res; 2006 Aug; 66(15):7824-31. PubMed ID: 16885387
[TBL] [Abstract][Full Text] [Related]
17. Preactivated oxazaphosphorines designed for isophosphoramide mustard delivery as bulk form or nanoassemblies: synthesis and proof of concept.
Skarbek C; Lesueur LL; Chapuis H; Deroussent A; Pioche Durieu C; Daville A; Caron J; Rivard M; Martens T; Bertrand JR; Le Cam E; Vassal G; Couvreur P; Desmaele D; Paci A
J Med Chem; 2015 Jan; 58(2):705-17. PubMed ID: 25494842
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
Ferrari S; Zolezzi C; Cesari M; Fasano MC; Lamanna G; Bacci G
Anticancer Drugs; 1999 Jan; 10(1):25-31. PubMed ID: 10194544
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells.
Patzer L; Hernando N; Ziegler U; Beck-Schimmer B; Biber J; Murer H
Kidney Int; 2006 Nov; 70(10):1725-34. PubMed ID: 17003823
[TBL] [Abstract][Full Text] [Related]
20. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
